# Coral Labs (NSE: CORALAB) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/CORALAB · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹196 Cr, it ranks 2280th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was 12.0% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹26 Cr (−5.9% year on year) and net profit ₹5 Cr (+84.5%), on a standalone basis. Promoters held 71.51% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹196 Cr |
| ROE | 12.0% (FY25) |
| ROCE | 16.3% (FY25) |
| Debt to equity | 0.02 |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹26 Cr | −5.9% | ₹5 Cr | +84.5% | ₹14.62 |
| Q3 FY26 | ₹22 Cr | −6.2% | ₹3 Cr | −54.7% | ₹7.77 |
| Q2 FY26 | ₹19 Cr | −41.0% | ₹6 Cr | −8.8% | ₹16.29 |
| Q1 FY26 | ₹19 Cr | −40.6% | ₹3 Cr | −70.9% | ₹7.18 |
| Q4 FY25 | ₹28 Cr | −2.6% | ₹3 Cr | −51.1% | ₹7.91 |
| Q3 FY25 | ₹23 Cr | +27.2% | ₹6 Cr | +184.3% | ₹17.20 |
| Q2 FY25 | ₹32 Cr | +39.2% | ₹6 Cr | +6.3% | ₹17.86 |
| Q1 FY25 | ₹32 Cr | +133.7% | ₹9 Cr | +378.3% | ₹24.64 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹115 Cr | ₹24 Cr |
| FY24 | ₹84 Cr | ₹16 Cr |
| FY23 | ₹78 Cr | ₹6 Cr |
| FY22 | ₹76 Cr | ₹9 Cr |
| FY21 | ₹97 Cr | ₹14 Cr |
| FY20 | ₹71 Cr | ₹7 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 71.51%
- Non-institutions: 28.49%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Syschem (India)](https://app.pivotnow.in/stock/SYSCHEM) | — | ₹214 Cr | — | — |
| [Achyut Health](https://app.pivotnow.in/stock/ACHYUT) | — | ₹209 Cr | — | — |
| [Aashka Hospital](https://app.pivotnow.in/stock/AASHKA) | — | ₹190 Cr | — | — |
| [Brooks Laboratories](https://app.pivotnow.in/stock/BROOKS) | ₹63.12 | ₹186 Cr | 7.6 | — |
| [OXYGENTA PHARMA](https://app.pivotnow.in/stock/OXYGENTAPH) | — | ₹185 Cr | — | — |
| [Accretion Nutra](https://app.pivotnow.in/stock/ANL) | — | ₹184 Cr | — | — |

## Questions and answers

### What is the market cap of Coral Labs?

Coral Labs' market capitalisation is ₹196 Cr (₹196 Cr) at the 22 Oct 2026 close, ranking 2280th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Coral Labs?

Return on equity was 12.0% in FY25 and return on capital employed was 16.3% in FY25 (standalone figures).

### Is Coral Labs a debt-free company?

Coral Labs is close to debt-free: its debt-to-equity ratio was 0.02 in FY25.

### What were Coral Labs' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Coral Labs reported revenue of ₹26 Cr, −5.9% year on year, and net profit of ₹5 Cr, +84.5% year on year.

### What is the shareholding pattern of Coral Labs?

As of 30 Jun 2026: promoters 71.51%, non-institutions 28.49%.

### Who are Coral Labs' competitors?

The listed Pharma & Healthcare companies closest to Coral Labs by market cap are Syschem (India), Achyut Health, Aashka Hospital, Brooks Laboratories, OXYGENTA PHARMA and Accretion Nutra.

### Is Coral Labs a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Coral Labs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on CORALAB against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.